JACC:生物可吸收支架和金属支架后的动脉重建

2017-06-27 xiangting MedSci原创

BVS扩张性血管壁重建比金属DES更频繁和更强,可以由患者的基线特征和围手术期因素来决定。

虽然之前的观察性研究已经记录了植入生物可吸收血管支架(BVS)后的深部扩大和扩张性重建,但没有与金属支架进行随机比较。

这项研究旨在比较吸收 BVS或Xience金属药物洗脱支架(DES)植入(Abbott Vascular,Santa Clara,California)后的血管重塑模式,并确定重塑的独立预测因子。

在ABSORB II随机试验中,术后和3年随访期内通过静脉内超声检查了383个病变(n = 359),根据3年内血管和管腔面积变化,总结了超过管腔和血管面积测量可重复性的9种血管重塑模式。

与DES相比,BVS平均血管面积的相对变化明显更大(6.7±12.6%vs.2.9±11.5%; p = 0.003); 平均管腔面积的相对变化在2组之间有显著差异(分别为1.4±19.1%vs -1.9±10.5%,p = 0.031)。多变量分析显示,使用BVS,女性,球动脉比> 1.25,扩张指数≥0.8,以前经皮冠脉介入治疗和较高水平的低密度脂蛋白胆固醇是广泛重塑的独立预测因素。此外,在BVS组中,术前核心坏死是广泛重塑的独立决定因素。

BVS扩张性血管壁重建比金属DES更频繁和更强,可以由患者的基线特征和围手术期因素来决定。观察到的管腔和血管重塑的临床效果需要进一步的大型临床研究,以优化生物可吸收支架治疗患者和病变的临床结局。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2017-07-15 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2017-09-07 hbwxf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2017-06-28 139****0239

    学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1926582, encodeId=b62a1926582b5, content=<a href='/topic/show?id=4c19961e039' target=_blank style='color:#2F92EE;'>#金属支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96170, encryptionId=4c19961e039, topicName=金属支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sat Jul 15 17:48:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076864, encodeId=835b20e6864ed, content=<a href='/topic/show?id=0b93692e416' target=_blank style='color:#2F92EE;'>#生物可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69274, encryptionId=0b93692e416, topicName=生物可吸收)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Aug 19 01:48:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030867, encodeId=c438203086ee0, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Thu Jun 07 16:48:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853668, encodeId=c2741853668f5, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 07 01:48:00 CST 2017, time=2017-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325409, encodeId=19ab132540938, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Jun 29 02:48:00 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216315, encodeId=946c2163157c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Wed Jun 28 12:20:44 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215950, encodeId=5a9621595035, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 27 12:15:35 CST 2017, time=2017-06-27, status=1, ipAttribution=)]
    2017-06-27 Y—xianghai

    学习了新知识

    0

相关资讯

Allergy:冠状动脉疾病患者:阿司匹林激发和/或脱敏的合格临床标准

超敏反应即异常的、过高的免疫应答。即机体与抗原性物质在一定条件下相互作用,产生致敏淋巴细胞或特异性抗体,如与再次进入的抗原结合,可导致机体生理功能紊乱和组织损害的免疫病理反应。又称变态反应。2017年3月,发表在《Allergy》的研究旨在在患有冠状动脉疾病的患者中建立阿司匹林的激发或脱敏的合格临床标准。背景:对阿司匹林(ASA)的超敏反应对于患有冠状动脉疾病的受试者构成严重的问题。在这些受试者中

SCCT 2014:CT血管造影结果支持2013 ACC/AHA指南

:心血管CT学会(SCCT)2014年会的一项报告表明,对于CT血管造影检出的冠脉闭塞患者,2013 ACC/AHA指南较2004 NCEP ATP III指南更有可能推荐他汀类治疗。 此项研究对来自于ROMICAT I试验的368例中危心血管疾病患者进行了分析,并排除了实际伴有临床急性冠脉综合征以及非40~75岁的患者。研究者依据两项指南对纳入最终分析的252例患者是否适用他汀类治疗进行了评估

JAHA:串联筛查识别的杂合家族性高胆固醇血症亲属的长期心血管风险

携带LDLR突变的杂合家族性高胆固醇血症亲属长期不良心血管事件的风险升高。

JACC:对症状稳定的冠脉疾病是采用功能测试还是冠脉造影?

对怀疑有冠脉疾病的稳定患者进行初步评估时,冠状动脉CTA与随后使用他汀类药物、阿司匹林和有创手术比例更高有相关性,治疗成本高于功能测试。

Thromb Haemost:SCAD的治疗—替格瑞洛能否取代氯吡格雷?

近期,Thromb Haemost杂志中的一篇报道,对替格瑞洛与氯吡格雷,在稳定性冠脉疾病(SCAD)伴有慢性阻塞性肺疾病(COPD)患者中的疗效进行了对比。这两种药物中,哪种药物对于改善动脉内皮功能的作用更优呢?对于SCAD合并有COPD的患者,其心血管不良事件的发生率较一般人显着提高。慢性炎症、上皮功能失调、氧化应激、及血小板活性(PR)的增强均是不良事件的诱因。46名SCAD合并COPD的患

Eur Heart J:冠脉疾病患者筛查糖尿病 **OGTT

瑞典一项研究表明,在伴有确定性冠脉疾病的患者中,口服糖耐量试验(OGTT)确认的既往未诊断糖尿病患者比率最高,并应作为评估类此患者血糖状况的首选检测。论文2月9日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究共纳入4004例既往无糖尿病病史的冠脉疾病患者,并测定空腹血糖(FPG)、2小时餐后血糖(2hPG)和糖化血红蛋白A1c(HbA1c)。依据ADA和WHO血糖异常标